Wednesday , November 20 2019
Home / philippines / Two new Ebola treatments show promise in combating outbreaks in Congo

Two new Ebola treatments show promise in combating outbreaks in Congo

(CNN) – The World Health Organization has decided to reduce the test for Ebola patients to two treatments that show real promise.

Treatments, known as REGN-EB3 and an antibody called mAb114, have been tried in Ebola patients in the Democratic Republic of Congo, along with ZMapp and Remdesivir antivirals.

The drug test began in November as part of an emergency response to outbreaks in Northern Kivu and Ituri provinces.

The current Ebola outbreak is now considered the second largest in history, killing at least 1,800 people. Violence in the region has limited efforts to combat the phenomenon.

The drugs REGN-EB3 and mAb114 showed "clearly better" results compared to others, according to the Data Surveillance and Safety Board (DSMB). The treatments were developed using antibodies collected from people who survived Ebola infection.

On Friday, the DSMB recommended that all future patients be given either REGN-EB3 or mAB114 after reviewing the results.

The study is an international effort co-sponsored and funded by the Congo INRB and the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health.

Dr. Anthony Shoach, NIAID director and one of the investigators leading the trial, said the results were "very good news" in the fight against Ebola.

"Obviously, this is a very important breakthrough," Fouchi said. Treatments will not stop the epidemic because it is done by finding contracts and identifying who is affected, he said.

But the results of the study show a real promise, he said, and could "save the lives of people who are unfortunate enough to be infected".

The results showed that 499 study participants who received REGN-EB3 or mAb114 had a better chance of survival compared to those who received other drugs.

Ebola patients who use these two drugs in the future will be enrolled in an expanded study to allow scientists to see if one works better than the other. The differences in patients' response to these two treatments in this initial test were "negligible".

Researchers working with the World Health Organization and pharmaceutical companies MappBio, Gilead, Regeneron and Ridgeback Biotherapeutics have been racing to find something to prevent Ebola.

This story was first published on "Two new Ebola treatments show promise in combating outbreaks in Congo"

Source link